Eli Lilly's stock rose 7% in a single day, marking its largest gain since early February when it surged 10% after releasing 2025 results. The rise reflects broader gains in the healthcare sector but is notably driven by the company's advancements in oncology and neuroscience, highlighting growth potential beyond its weight loss treatments. Despite risks from falling prices of key drugs, Eli Lilly's stock remains below its 2026 target price, suggesting room for further growth.
Starting July 1, Medicare will cover obesity drugs for eligible seniors through its new Bridge demonstration program, requiring a $50 monthly copay. This marks a major expansion in access to treatments from Novo Nordisk and Eli Lilly, previously unaf...
Shares of AbbVie, Eli Lilly, and Johnson & Johnson are reaching all-time highs, reflecting renewed investor interest in the biopharmaceutical sector. AbbVie's recent announcement to acquire Apogee Therapeutics boosted its stock by 12%. Analysts attri...
Eli Lilly's shares rose nearly 6% following the European Medicines Agency's CHMP recommendation to approve Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all therapy lines. This approval would allow use regardless ...
GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are driving high demand among employees, but their high costs are causing many large employers to reduce or reconsider coverage. Although oral pills are as expensive as injectables and less effe...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for treating adults with chronic lymphocytic leukemia (CLL) across all lin...
